SILVER SPRING, Md., Dec. 19, 2017 /PRNewswire-USNewswire/ — The U.S. Food and Drug Administration today approved Luxturna (voretigene neparvovec-rzyl), a new gene therapy, to treat children and adult patients with an inherited form of vision loss that may result in blindness. Luxturna is…
